Smoking cessation - The contribution of community pharmacy

被引:4
|
作者
McElnay, JC [1 ]
Maguire, TA [1 ]
Drummond, A [1 ]
Hughes, CM [1 ]
机构
[1] Queens Univ Belfast, Sch Pharm, Belfast BT9 7BL, Antrim, North Ireland
关键词
D O I
10.2165/00115677-200008030-00004
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Smoking accounts for significant morbidity and mortality and has major economic consequences for healthcare delivery throughout the world. Government policy such as increasing taxes and restricting advertising go some way to reduce smoking,but the social and economic factors that affect target populations will impact on the success of any strategy. Public health interventions can also contribute to increasing cessation rates. The most successful interventions appear to be those characterised by personalised advice and assistance, repeated in different forms over the longest feasible period of time. Pharmacological aids, which are important components of a cessation programme, include nicotine replacement therapy in the form of chewing gum, patches, nasal spray, oral inhaler or sublingual tablets; bupropion (amfebutamone) has been approved for use in some countries. As the community pharmacy is the major point of supply of such products, the pharmacist is in a key position to encourage and support clients who wish to stop smoking. A number of studies have examined the role of the community pharmacist in assisting smokers through the so-called 'cycle of change'. These studies have utilised a model that offers individualised advice through a motivational technique to encourage a change in behaviour; nicotine replacement therapy is optional. Follow-up is an essential part of these programmes to monitor progress and to provide additional support. Evaluations of these pharmacy-based initiatives have confirmed the importance of a multifaceted approach in achieving success in smoking cessation, i.e. behaviour modification, nicotine replacement therapy and client support.
引用
收藏
页码:147 / 158
页数:12
相关论文
共 50 条
  • [1] Community pharmacy personnel interventions for smoking cessation
    Carson-Chahhoud, Kristin V.
    Livingstone-Banks, Jonathan
    Sharrad, Kelsey J.
    Kopsaftis, Zoe
    Brinn, Malcolm P.
    To-A-Nan, Rachada
    Bond, Christine M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (10):
  • [2] Take a breath: a community pharmacy service for smoking cessation
    Paulino, Ema
    Ferreira, Catarina
    Pinto, Ana
    Rosa, Mariana
    Teixeira, Luisa
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2021, 43 (06) : 1760 - 1760
  • [3] Smoking cessation and pharmacy
    Neto, AD
    Benrimoj, C
    AUSTRALIAN JOURNAL OF PHARMACY, 2001, 82 (974): : 408 - 409
  • [4] DEVELOPMENT OF COMMUNITY PHARMACY TO THE CENTER OF SMOKING CESSATION, INITIATIVE IN THAILAND
    Lertsinudom, Sunee
    Kaewketthong, Pentipa
    Tunpichart, Sirirat
    RESPIROLOGY, 2018, 23 : 150 - 151
  • [5] Meta-analysis of the effectiveness of smoking cessation interventions in community pharmacy
    Saba, M.
    Diep, J.
    Saini, B.
    Dhippayom, T.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2014, 39 (03) : 240 - 247
  • [6] The impact of pharmacist-led smoking cessation program at community pharmacy
    Atalay, Leyla
    Sancar, Mesut
    Okuyan, Betul
    Izzettin, Fikret Vehbi
    CLINICAL AND EXPERIMENTAL HEALTH SCIENCES, 2012, 2 (01): : 20 - 25
  • [7] A Workshop on Smoking Cessation for Pharmacy Students
    Saba, Maya
    Bittoun, Renee
    Saini, Bandana
    AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION, 2013, 77 (09)
  • [8] Approach to smoking cessation of a patient from the community pharmacy. 'CESAR' program
    Carlos Gomez-Martinez, Jesus
    Tejedor-Garcia, Noelia
    Garcia-Pastor, Coral
    FARMACEUTICOS COMUNITARIOS, 2020, 12 (01): : 25 - 28
  • [9] Smoking cessation in community pharmacy practice-a clinical information needs analysis
    Saba, Maya
    Bittoun, Renee
    Kritikos, Vicky
    Saini, Bandana
    SPRINGERPLUS, 2013, 2 : 1 - 13
  • [10] Smoking cessation in the pharmacy, why and how?
    Faure, Sebastien
    ACTUALITES PHARMACEUTIQUES, 2014, 53 (535): : 19 - 19